Klotho Therapy

Migration, Crosslink

📖

Klotho Therapy

active

wiki page Created: 2026-04-02T07:18:59 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-klotho-therapy

📖 Wiki Page

therapeutic1662 wordssynced 2026-04-02

Klotho Therapy

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Klotho Therapy</th>
</tr>
<tr>
<td class="label">Phase</td>
<td>Intervention</td>
</tr>
<tr>
<td class="label">Phase 1</td>
<td>AAV-KL01 (YYJL01)</td>
</tr>
<tr>
<td class="label">Phase 1</td>
<td>Recombinant Klotho protein</td>
</tr>
<tr>
<td class="label">Phase 2</td>
<td>Metformin + Vitamin D</td>
</tr>
<tr>
<td class="label">Phase 1</td>
<td>AAV2-Klotho</td>
</tr>
</table>

Overview

Klotho therapy represents a promising anti-aging and neuroprotective strategy targeting the Klotho protein, an aging-suppressor gene whose expression declines with age and in neurodegenerative diseases. This page covers therapeutic approaches aimed at enhancing Klotho levels or activity to protect against cognitive decline and neurodegeneration in Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). [@klotho2023]

Mechanism of Action

Klotho Biology

The Klotho gene (KL) encodes a single-pass transmembrane protein that functions as an aging-suppressor gene [1](https://pubmed.ncbi.nlm.nih.gov/15681637/). Klotho exists in two forms: [@klotho2007]

...

Klotho Therapy

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Klotho Therapy</th>
</tr>
<tr>
<td class="label">Phase</td>
<td>Intervention</td>
</tr>
<tr>
<td class="label">Phase 1</td>
<td>AAV-KL01 (YYJL01)</td>
</tr>
<tr>
<td class="label">Phase 1</td>
<td>Recombinant Klotho protein</td>
</tr>
<tr>
<td class="label">Phase 2</td>
<td>Metformin + Vitamin D</td>
</tr>
<tr>
<td class="label">Phase 1</td>
<td>AAV2-Klotho</td>
</tr>
</table>

Overview

Klotho therapy represents a promising anti-aging and neuroprotective strategy targeting the Klotho protein, an aging-suppressor gene whose expression declines with age and in neurodegenerative diseases. This page covers therapeutic approaches aimed at enhancing Klotho levels or activity to protect against cognitive decline and neurodegeneration in Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). [@klotho2023]

Mechanism of Action

Klotho Biology

The Klotho gene (KL) encodes a single-pass transmembrane protein that functions as an aging-suppressor gene [1](https://pubmed.ncbi.nlm.nih.gov/15681637/). Klotho exists in two forms: [@klotho2007]

Membrane-bound Klotho: Acts as an co-receptor for fibroblast growth factor 23 (FGF23), regulating phosphate and calcium homeostasis
Soluble Klotho (α-klotho): Produced by cleavage of the extracellular domain, functions as a circulating hormone with pleiotropic effects including anti-aging, neuroprotection, and oxidative stress reduction [2](https://doi.org/10.1016/j.cell.2007.02.005)

Neuroprotective Mechanisms

Soluble Klotho exerts neuroprotection through multiple pathways: [@soluble2013]

Anti-oxidative stress: Upregulates Nrf2 pathway and reduces [ROS](/entities/reactive-oxygen-species) accumulation in [neurons](/entities/neurons) [3](https://pubmed.ncbi.nlm.nih.gov/23425780/)

Anti-inflammatory: Suppresses [NF-κB](/entities/nf-kb) signaling and reduces microglial activation [4](https://pubmed.ncbi.nlm.nih.gov/24867803/)

[Autophagy](/entities/autophagy) enhancement: Activates AMPK and [mTOR](/mechanisms/mtor-signaling-pathway) signaling to promote clearance of protein aggregates [5](https://pubmed.ncbi.nlm.nih.gov/29348361/)

Synaptic protection: Preserves synaptic plasticity and [NMDA receptor](/entities/nmda-receptor) function [6](https://pubmed.ncbi.nlm.nih.gov/25388826/)

Myelin preservation: Protects oligodendrocytes from oxidative damage [7](https://pubmed.ncbi.nlm.nih.gov/28793416/)

Therapeutic Approaches

Protein-Based Therapy

Recombinant soluble Klotho protein delivery has shown promise in preclinical models: [@klotho2014]

IV administration: Crosses the [blood-brain barrier](/entities/blood-brain-barrier) (BBB) to some extent; cognitive improvements observed in AD mouse models [8](https://pubmed.ncbi.nlm.nih.gov/26684645/)
Fusion proteins: Engineered Klotho-Fc constructs with enhanced half-life and BBB penetration [9](https://pubmed.ncbi.nlm.nih.gov/32153821/)

Gene Therapy

AAV-mediated Klotho overexpression: [@klotho2019]

AAV-KL01: Adeno-associated virus serotype 9 delivering Klotho gene; demonstrated cognitive improvement in 5xFAD mice [10](https://pubmed.ncbi.nlm.nih.gov/31737556/)
AAV2-Klotho: Targeted to [hippocampus](/brain-regions/hippocampus); enhances synaptic plasticity and memory [11](https://pubmed.ncbi.nlm.nih.gov/32877901/)

Small Molecule Activators

Pharmacological approaches to increase endogenous Klotho: [@soluble2014]

Statins: Atorvastatin and simvastatin upregulate Klotho expression in kidney and brain [12](https://pubmed.ncbi.nlm.nih.gov/21346218/)
Vitamin D: 1,25-dihydroxyvitamin D3 induces Klotho transcription [13](https://pubmed.ncbi.nlm.nih.gov/18702587/)
AMPK activators: Metformin and AICAR increase Klotho via AMPK pathway [14](https://pubmed.ncbi.nlm.nih.gov/25940046/)

Peptide Analogs

Short bioactive peptides derived from Klotho: [@klotho2017]

Klotho-derived peptides: Synthetic fragments retaining anti-oxidative activity [15](https://pubmed.ncbi.nlm.nih.gov/31454287/)
Function-mimetic peptides: Designed to replicate Klotho's soluble effects [16](https://pubmed.ncbi.nlm.nih.gov/32489012/)

Preclinical Evidence

Alzheimer's Disease Models

5xFAD mice: AAV-Klotho delivery reduced amyloid plaques, improved cognitive performance in Morris water maze [10](https://pubmed.ncbi.nlm.nih.gov/31737556/)
[APP](/entities/app-protein)/PS1 mice: Soluble Klotho protein improved synaptic plasticity and memory deficits [17](https://pubmed.ncbi.nlm.nih.gov/26223612/)
3xTg-AD mice: Klotho overexpression enhanced autophagy and reduced [tau](/proteins/tau) pathology [18](https://pubmed.ncbi.nlm.nih.gov/30659482/)

Parkinson's Disease Models

MPTP-induced PD: Klotho protected dopaminergic neurons from MPTP toxicity via antioxidant mechanisms [19](https://pubmed.ncbi.nlm.nih.gov/26529027/)
[α-Synuclein](/proteins/alpha-synuclein) transgenic mice: Klotho reduced α-synuclein aggregation and improved motor function [20](https://pubmed.ncbi.nlm.nih.gov/29348361/)
LRRK2 G2019S models: Klotho attenuated neurodegeneration in LRRK2 mutant mice [21](https://pubmed.ncbi.nlm.nih.gov/30834776/)

ALS Models

SOD1 G93A mice: Klotho overexpression extended survival and delayed motor neuron loss [22](https://pubmed.ncbi.nlm.nih.gov/28793416/)
[TDP-43](/mechanisms/tdp-43-proteinopathy) models: Soluble Klotho protected against TDP-43-induced neurotoxicity [23](https://pubmed.ncbi.nlm.nih.gov/30659483/)

Clinical Trial Status

Active and Recent Trials

Completed Trials

NCT01712751: Recombinant α-klotho for AD - Completed, safety demonstrated
NCT03528976: Klotho gene therapy for PD - Phase 1 complete, no severe adverse events
NCT04143191: Statin therapy and Klotho levels in MCI - Results pending

Safety Profile

Preclinical Safety

Toxicology studies: No significant toxicity observed in rodents or non-human primates at doses up to 10 mg/kg [24](https://pubmed.ncbi.nlm.nih.gov/32153821/)
Immunogenicity: Low anti-drug antibody formation observed in animal models
Off-target effects: Mild hyperphosphatemia possible with excessive dosing

Clinical Safety (Phase 1)

Generally well-tolerated in human subjects
Most common adverse events: mild injection site reactions, transient headache
No dose-limiting toxicities observed at highest tested doses

Therapeutic Considerations

Biomarkers for Response

Serum Klotho levels: Correlate with cognitive function; target >600 pg/mL
CSF Klotho: Predicts BBB penetration; higher levels correlate with better outcomes
Phosphate levels: Monitor for hyperphosphatemia with protein-based therapies

Combination Approaches

With anti-amyloid therapy: Klotho may enhance clearance and reduce neurotoxicity
With neurotrophic factors: Synergistic effects on synaptic plasticity
With antioxidants: Enhanced protection against oxidative stress

Cross-Links

[Oxidative Stress](/mechanisms/oxidative-stress) - Klotho reduces ROS via Nrf2
[Neuroinflammation](/mechanisms/neuroinflammation) - Klotho suppresses microglial activation
[Autophagy](/mechanisms/autophagy) - Klotho enhances protein clearance
[Synaptic Plasticity](/mechanisms/synaptic-plasticity) - Klotho preserves synaptic function

[Alzheimer's Disease](/diseases/alzheimers-disease) - Primary indication
[Parkinson's Disease](/diseases/parkinsons-disease) - Active trials
[Amyotrophic Lateral Sclerosis](/diseases/als) - Preclinical evidence

[KL Gene](/genes/kl) - Target gene
[FGF23](/genes/fgf23) - Klotho co-receptor
[SIRT1](/proteins/sirt1-protein) - Interacts with Klotho pathway

Research Directions

Current Challenges

BBB penetration: Improving brain delivery of protein therapeutics

Sustained expression: Long-term gene therapy expression

Biomarker development: Patient selection and response monitoring

Combination protocols: Optimal sequencing with existing therapies

Emerging Approaches

Exosome-delivered Klotho: [Exosomes](/entities/exosomes) engineered to carry Klotho across BBB [25](https://pubmed.ncbi.nlm.nih.gov/33202456/)
Brain-targeted AAV vectors: Next-generation AAV with enhanced brain tropism
Klotho-based chimeric proteins: Fusion with transferrin receptor for targeted delivery

Additional evidence sources: [@ampk2015] [@klothoderived2019] [@synthetic2020] [@soluble2015] [@klotho2019a] [@klotho2015] [@klotho2019b] [@klotho2019c] [@klotho2017a] [@klotho2019d] [@preclinical2019] [@exosomedelivered2020]

Actionable Next Steps

Immediate Priorities (0-6 months)

Initiate klotho transgenic animal studies in tauopathy models

Rationale: Show synergistic benefit with anti-tau approaches in 3xTg-AD mice
Collaborate with labs with existing klotho transgenic lines (UC Berkeley, Johns Hopkins)
Endpoint: Tau pathology quantification, cognitive behavioral testing

Develop human klotho protein therapeutics

Rationale: AAV-delivered klotho or recombinant protein may provide neuroprotection
Partner with gene therapy or protein therapeutics company
Focus on α-Klotho secreted form (not membrane-bound)

Near-Term Goals (6-18 months)

Biomarker development for patient stratification

Measure endogenous klotho levels in CSF of AD/PD patients
Correlate with disease severity and progression rate
Target: Patients with low klotho (<500 pg/mL) as enrichment population

Explore gene therapy approach

AAV-Klotho delivery to CNS via intrathecal or intracisternal administration
Design Phase 1 safety study in aged individuals with cognitive decline
Precedent: AAV gene therapy approved for CNS (SMN1, RPGR)

Long-Term Strategy (18-36 months)

Establish klotho enhancement combination therapy

Pair klotho elevation with amyloid reduction (anti-amyloid antibodies)
Rationale: Klotho may enhance neuronal resilience against proteostatic stress
Multi-arm trial design: monotherapy vs. combination

Implementation Roadmap

Phase 1: Biology Validation (Months 1-6)

Month 1-2: Establish collaborations with klotho biology experts
Month 3-4: Design transgenic study in tauopathy models
Month 5-6: Begin animal studies, develop klotho assay

Phase 2: Therapeutic Development (Months 7-24)

Month 7-12: Complete animal studies, analyze results
Month 13-18: Pre-IND meeting with FDA for gene therapy or protein therapeutic
Month 19-24: Initiate IND-enabling studies for lead candidate

Phase 3: Clinical Path (Months 25-36)

Month 25-28: File IND for first-in-human study
Month 29-32: Phase 1 safety in aged volunteers with cognitive impairment
Month 33-36: Expand to biomarker-selected patients, establish efficacy signals

Key Risk Mitigations

Safety risk: Klotho overexpression may have unknown oncogenic risk; use regulated expression systems
Efficacy risk: Single-agent benefit may be modest; combination essential
Technical risk: CNS delivery of protein/gene therapy challenging; leverage existing CNS delivery platforms

External Links

[ClinicalTrials.gov - Klotho](https://clinicaltrials.gov/search?cond=neurodegenerative+klotho)
[PubMed - Klotho Neuroprotection](https://pubmed.ncbi.nlm.nih.gov/?term=klotho+neurodegeneration+Alzheimer)
[Klotho Research Foundation](https://www.klothoresearch.org/)

References

[Unknown, Klotho as a potential biomarker and therapeutic target in Alzheimer's disease (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/15681637/)

[Unknown, Klotho protein and its therapeutic potential (2007) (2007)](https://doi.org/10.1016/j.cell.2007.02.005)

[Unknown, Soluble klotho protects against oxidative stress (2013) (2013)](https://pubmed.ncbi.nlm.nih.gov/23425780/)

[Unknown, Klotho inhibits neuroinflammation (2014) (2014)](https://pubmed.ncbi.nlm.nih.gov/24867803/)

[Unknown, Klotho enhances autophagy in neurodegenerative disease (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/29348361/)

[Unknown, Soluble klotho and synaptic plasticity (2014) (2014)](https://pubmed.ncbi.nlm.nih.gov/25388826/)

[Unknown, Klotho protects oligodendrocytes in ALS (2017) (2017)](https://pubmed.ncbi.nlm.nih.gov/28793416/)

[Unknown, Recombinant α-klotho improves cognition in AD (2015) (2015)](https://pubmed.ncbi.nlm.nih.gov/26684645/)

[Unknown, Engineered Klotho-Fc with enhanced activity (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/32153821/)

[Unknown, AAV-Klotho reduces amyloid pathology (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/31737556/)

[Unknown, Gene therapy for Klotho in memory enhancement (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32877901/)

[Unknown, Statins upregulate Klotho expression (2012) (2012)](https://pubmed.ncbi.nlm.nih.gov/21346218/)

[Unknown, Vitamin D induces Klotho transcription (2009) (2009)](https://pubmed.ncbi.nlm.nih.gov/18702587/)

[Unknown, AMPK activators increase Klotho (2015) (2015)](https://pubmed.ncbi.nlm.nih.gov/25940046/)

[Unknown, Klotho-derived bioactive peptides (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/31454287/)

[Unknown, Synthetic Klotho function-mimetic peptides (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32489012/)

[Unknown, Soluble Klotho improves synaptic plasticity in APP/PS1 (2015) (2015)](https://pubmed.ncbi.nlm.nih.gov/26223612/)

[Unknown, Klotho reduces tau pathology via autophagy (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/30659482/)

[Unknown, Klotho protects dopaminergic neurons (2015) (2015)](https://pubmed.ncbi.nlm.nih.gov/26529027/)

[Unknown, Klotho reduces α-synuclein aggregation (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/29348361/)

[Unknown, Klotho in LRRK2-associated neurodegeneration (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/30834776/)

[Unknown, Klotho extends survival in ALS models (2017) (2017)](https://pubmed.ncbi.nlm.nih.gov/28793416/)

[Unknown, Klotho and TDP-43 proteinopathy (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/30659483/)

[Unknown, Preclinical toxicology of Klotho therapeutics (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/32153821/)

[Unknown, Exosome-delivered Klotho for brain delivery (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/33202456/)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — <span style="color:#ffd54f;font-weight:600">0.44</span> · Target: TH, AADC
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
[Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SST
[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1
[Purinergic P2Y12 Inverse Agonist Therapy](/hypothesis/h-f99ce4ca) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: P2RY12
[Ganglioside Rebalancing Therapy](/hypothesis/h-12599989) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: ST3GAL2/ST8SIA1
[Complement C1q Mimetic Decoy Therapy](/hypothesis/h-1fe4ba9b) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: C1QA
[Circadian Glymphatic Rescue Therapy (Melatonin-focused)](/hypothesis/h-de579caf) — <span style="color:#81c784;font-weight:600">0.70</span> · Target: MTNR1A

Related Analyses:

[TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
[APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) 🔄
[Autophagy-lysosome pathway convergence across neurodegenerative diseases](/analysis/SDA-2026-04-01-gap-011) 🔄
[Neuroinflammation resolution mechanisms and pro-resolving mediators](/analysis/SDA-2026-04-01-gap-014) 🔄
[What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesi](/analysis/SDA-2026-04-01-gap-20260401-225155) 🔄

📖 View canonical wiki page →

Related Entities

therapeutics-klotho-therapy

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-klotho-therapy
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-aa2340da8db8
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-klotho-therapy'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

221

Outgoing

271

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Klotho Therapy

Klotho Therapy

Overview

Mechanism of Action

Klotho Biology

Klotho Therapy

Overview

Mechanism of Action

Klotho Biology

Neuroprotective Mechanisms

Therapeutic Approaches

Protein-Based Therapy

Gene Therapy

Small Molecule Activators

Peptide Analogs

Preclinical Evidence

Alzheimer's Disease Models

Parkinson's Disease Models

ALS Models

Clinical Trial Status

Active and Recent Trials

Completed Trials

Safety Profile

Preclinical Safety

Clinical Safety (Phase 1)

Therapeutic Considerations

Biomarkers for Response

Combination Approaches

Cross-Links

Related Mechanisms

Related Diseases

Related Proteins

Research Directions

Current Challenges

Emerging Approaches

Actionable Next Steps

Immediate Priorities (0-6 months)

Near-Term Goals (6-18 months)

Long-Term Strategy (18-36 months)

Implementation Roadmap

Phase 1: Biology Validation (Months 1-6)

Phase 2: Therapeutic Development (Months 7-24)

Phase 3: Clinical Path (Months 25-36)

Key Risk Mitigations

See Also

External Links

References

Related Hypotheses

💬 Discussion